Ajay Singh

Ajay Singh

Auto-generated profile, based on publicly available information

Ajay Singh

SUNY Buffalo, Inst Lasers Photon & Biophoton, Buffalo, NY 14260 USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2012 in ACS Nano
Verified
Journal Article
Closed access
YLYong-Deok Lee
Yong-Deok Lee
CLChang-Keun Lim
Chang-Keun Lim
ASAjay Singh
Ajay Singh
Joonseok KohJoonseok Koh
Joonseok Koh
JKJungahn Kim
Jungahn Kim
SKSehoon Kim
Sehoon Kim

17 July 2017 in Journal of Drug Targeting
Verified
Journal Article
Closed access
RARavikumar Aalinkeel
Ravikumar Aalinkeel
HKHilliard L. Kutscher
Hilliard L. Kutscher
ASAjay Singh
Ajay Singh
KCKatherine Cwiklinski
Katherine Cwiklinski
NKNoor Khechen
Noor Khechen
Supriya MahajanSupriya Mahajan
Supriya Mahajan
It is well established that overproduction and accumulation of the β-amyloid (Aβ) peptide 1–42 (Aβ(1–42)) is a trigger of the pathological cascade in Alzheimer’s disease (AD) that manifests as cognitive impairment. Ginsenoside Rg3 is an important constituent of ginseng, plays an essential role in memory and improved cognition, and is known to produce antioxidant effects via the reduction of free radicals. Therefore, ginsenoside Rg3 may be a promising candidate as a neuroprotective agent for the treatment of AD. A novel nanotherapeutic strategy that enhances delivery of ginsenosides to the brain by increasing its transport across the blood brain barrier (BBB) would facilitate neuroprotection and limit the accumulation of Aβ plaques and subsequent neurodegeneration. In this current study, we formulated and characterised biodegradable poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) that encapsulate ginsenoside Rg3 and Thioflavin T, an Aβ diagnostic; examine its neuroprotective effects; investigate key mechanisms that may underlie its neuroprotective effects; and evaluate its ability to cross the BBB using an in vitro BBB model. Our PLGA-Rg3 NPs offers an exciting new theranostic material capable of encapsulating natural nutraceuticals for the detection and treatment of AD. In addition, this nanotechnology strategy can be adapted to treat other neurological diseases, utilising many natural therapeutic agents which are limited by their solubility and/or poor pharmacokinetics.

1 April 2016 in Biomaterials
Verified
Journal Article
Closed access
YSYoung Hun Seo
Young Hun Seo
ASAjay Singh
Ajay Singh
HCHong-Jun Cho
Hong-Jun Cho
YKYoungsun Kim
Youngsun Kim
JHJeongyun Heo
Jeongyun Heo
SKSehoon Kim
Sehoon Kim

1 September 2013 in Biomaterials
Verified
Journal Article
Closed access
CLChang-Keun Lim
Chang-Keun Lim
ASAjay Singh
Ajay Singh
JHJeongyun Heo
Jeongyun Heo
DKDaehong Kim
Daehong Kim
KLKyung Eun Lee
Kyung Eun Lee
SKSehoon Kim
Sehoon Kim

5 September 2016 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
ASAjay Singh
Ajay Singh
WKWoong Kim
Woong Kim
YKYoungsun Kim
Youngsun Kim
KJKeunsoo Jeong
Keunsoo Jeong
CKChi Soo Kang
Chi Soo Kang
SKSehoon Kim
Sehoon Kim

18 June 2013 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
ASAjay Singh
Ajay Singh
CLChang-Keun Lim
Chang-Keun Lim
YLYong-Deok Lee
Yong-Deok Lee
JMJoon-Ho Maeng
Joon-Ho Maeng
SLSangyoup Lee
Sangyoup Lee
SKSehoon Kim
Sehoon Kim